These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 14526258)

  • 1. [Anti-glioma vaccination].
    Delhaye M; Clavreul A; Garcion E; Menei P
    Neurochirurgie; 2003 Sep; 49(4):459-63. PubMed ID: 14526258
    [No Abstract]   [Full Text] [Related]  

  • 2. Cellular immunity in the treatment of brain tumors.
    Wheeler CJ; Yu JS; Black KL
    Clin Neurosurg; 2004; 51():132-9. PubMed ID: 15571138
    [No Abstract]   [Full Text] [Related]  

  • 3. Harnessing the immune system against human glioma.
    Dhodapkar KM; Banerjee D; Steinman RM
    Ann N Y Acad Sci; 2005 Dec; 1062():13-21. PubMed ID: 16461784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma-specific antigens for immune tumor therapy.
    Skog J
    Expert Rev Vaccines; 2006 Dec; 5(6):793-802. PubMed ID: 17184218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
    Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
    Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-stage progress on glioma vaccines.
    Brower V
    J Natl Cancer Inst; 2011 Sep; 103(18):1361-2. PubMed ID: 21881038
    [No Abstract]   [Full Text] [Related]  

  • 7. Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma.
    Fenstermaker RA; Ciesielski MJ
    Expert Rev Vaccines; 2014 Mar; 13(3):377-85. PubMed ID: 24521310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines for glioblastoma and high-grade glioma.
    Wheeler CJ; Black KL
    Expert Rev Vaccines; 2011 Jun; 10(6):875-86. PubMed ID: 21692706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer vaccines: a novel strategy to sensitize malignant glioma to chemotherapy.
    Liu G; Yu JS
    Expert Rev Neurother; 2007 Oct; 7(10):1235-7. PubMed ID: 17939761
    [No Abstract]   [Full Text] [Related]  

  • 10. Cellular immune response in brain tumors.
    Streit WJ
    Neuropathol Appl Neurobiol; 1994 Apr; 20(2):205-6. PubMed ID: 8072665
    [No Abstract]   [Full Text] [Related]  

  • 11. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
    Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
    Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Peptide vaccination therapy for malignant glioma].
    Yamanaka R; Itoh K
    Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glioma and intracerebral immunity].
    Shimizu K
    No To Shinkei; 1997 Mar; 49(3):239-50. PubMed ID: 9125729
    [No Abstract]   [Full Text] [Related]  

  • 14. Research reinforces potential allergies-glioma connection.
    Martin M
    J Natl Cancer Inst; 2012 Mar; 104(5):353-6. PubMed ID: 22349202
    [No Abstract]   [Full Text] [Related]  

  • 15. Personalized, multivalent, and more affordable: the globalization of vaccines.
    Debinski W
    Clin Cancer Res; 2005 Aug; 11(16):5663-4. PubMed ID: 16115899
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor fighter.
    Kiser K
    Minn Med; 2012 Jan; 95(1):16-9. PubMed ID: 22355905
    [No Abstract]   [Full Text] [Related]  

  • 17. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
    Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
    Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
    Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R
    Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological considerations and the malignant glioma problem.
    Mahaley MS
    Clin Neurosurg; 1968; 15():175-89. PubMed ID: 4333303
    [No Abstract]   [Full Text] [Related]  

  • 20. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.
    de Vleeschouwer S; Rapp M; Sorg RV; Steiger HJ; Stummer W; van Gool S; Sabel M
    Neurosurgery; 2006 Nov; 59(5):988-99; discussioin 999-1000. PubMed ID: 17143233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.